Objectives

- Review current approvals and large published trials of PARP inhibitors in frontline treatment of ovarian cancer
  - Review data for HRD testing
- Review role of PARP inhibitors in maintenance of platinum-sensitive ovarian cancer
- Review the role of PARP inhibitors in the treatment of recurrent ovarian cancer
  - Importance of platinum sensitivity
  - Importance of BRCA reversion mutations